Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.Continue reading
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family office, Mirabaud bank and previous investors.
Peter Ibbotson, who has recently been promoted to the position of a Partner at Swisscom Ventures will replace Dominique Mégret on the Board of Directors of Scailyte.
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in endometriosis.Continue reading
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and to advance personalized cancer treatment.Continue reading
Bringing industry and academia together to discuss the potential impact of single-cell analytics powered by machine learning for precision medicine.Continue reading
Register for Scailyte’s webinar on “Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies”.webinar single-cell endometriosis researchContinue reading
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cell data analysis.Continue reading
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cell data analysis.Continue reading
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision medicine through single-cell science.Continue reading
Scailyte AG announces a strategic partnership with Sirona DX for AI-driven end-point specific single-cell analysis.Continue reading